- Joined
- Nov 22, 2020
Huh yeah it works if you google it. Thanks.Here you are. The direct link didn't work for some reason, but putting the URL into a search engine and accessing it that way did.
Using Google Translate it's a bit wonky, to be honest I can't really tell if they're saying they already concluded the clinical trials or they are currently running them. Also lol what's that line about elephants at the end?
Kowa Co., Ltd. (hereinafter referred to as "Kowa") is a new coronavirus (SARS-CoV-2) infectious disease.
The investigational drug "Ibe" used in the phase III clinical trial (development code: K-237) for treatment.
Regarding "Lumectin", from the joint research (non-clinical study) with Kitasato University, the existing For the Omicron strain as well as the mutant strain (alpha beta gamma delta strain)
However, we have confirmed that it has the same antiviral effect. Kowa, as he announced in July 2021, won the Nobel Prize in Physiology or Medicine Satoshi Omura.
Treatment for new coronavirus infections directly from Kitasato University Special Honorary Professor He was asked to conduct a clinical trial of ivermectin as a drug. New model Pharmaceuticals contribute to the treatment of Lonavirus infections and protect the health of the people Considering the company's mission, the effectiveness of ivermectin against new coronavirus infections As well as conducting clinical trials to confirm safety, he is.
Ivermectin has been used by WHO as a treatment for parasitic infections in infected areas for over 30 years. Is distributed. Volunteers distribute directly to people, especially in some African countries It has been confirmed to be safe enough.
In addition, ivermectin is intracellular in SARS-CoV-2. It has been reported that it suppresses invasion into the drug and inhibits replication, and is used as drug repositioning. It is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases.
In this clinical trial, the dosage and administration already approved as a therapeutic agent for parasitic infections Although it is different, we are confirming its efficacy and safety in clinical trials.
Kowa confirmed the clinical effect of ivermectin on SARS-CoV-2 and was one of the first to the public.
By providing it to everyone, we will contribute to the treatment of new coronavirus infectious diseases as much as possible.
* Overseas, patients use high-content ivermectin for animals, which is dangerous to humans, and it is harmful. Although it was reported that elephants will appear, Kowa is the standard for conducting clinical trials of pharmaceuticals in humans. Ibermek in accordance with the strict standards stipulated in the "GCP (Good Clinical Practice)" We are conducting clinical trials of chin.
The investigational drug "Ibe" used in the phase III clinical trial (development code: K-237) for treatment.
Regarding "Lumectin", from the joint research (non-clinical study) with Kitasato University, the existing For the Omicron strain as well as the mutant strain (alpha beta gamma delta strain)
However, we have confirmed that it has the same antiviral effect. Kowa, as he announced in July 2021, won the Nobel Prize in Physiology or Medicine Satoshi Omura.
Treatment for new coronavirus infections directly from Kitasato University Special Honorary Professor He was asked to conduct a clinical trial of ivermectin as a drug. New model Pharmaceuticals contribute to the treatment of Lonavirus infections and protect the health of the people Considering the company's mission, the effectiveness of ivermectin against new coronavirus infections As well as conducting clinical trials to confirm safety, he is.
Ivermectin has been used by WHO as a treatment for parasitic infections in infected areas for over 30 years. Is distributed. Volunteers distribute directly to people, especially in some African countries It has been confirmed to be safe enough.
In addition, ivermectin is intracellular in SARS-CoV-2. It has been reported that it suppresses invasion into the drug and inhibits replication, and is used as drug repositioning. It is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases.
In this clinical trial, the dosage and administration already approved as a therapeutic agent for parasitic infections Although it is different, we are confirming its efficacy and safety in clinical trials.
Kowa confirmed the clinical effect of ivermectin on SARS-CoV-2 and was one of the first to the public.
By providing it to everyone, we will contribute to the treatment of new coronavirus infectious diseases as much as possible.
* Overseas, patients use high-content ivermectin for animals, which is dangerous to humans, and it is harmful. Although it was reported that elephants will appear, Kowa is the standard for conducting clinical trials of pharmaceuticals in humans. Ibermek in accordance with the strict standards stipulated in the "GCP (Good Clinical Practice)" We are conducting clinical trials of chin.